PDCD1 and neoplasm: The overall efficacy of EMB-02 was modest, with an ORR and DCR of 6.4% and 44.7%, respectively, however generally comparable with other anti-PD-1 and anti-LAG-3 bispecific antibodies in dose escalation studies which did not for selected tumor type [20, 23].